Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 19 Dec 17

The "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Discovery stages are 1, 6 and 1 respectively.

Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Female Hypoactive Sexual Desire Disorder - Overview
  2. Female Hypoactive Sexual Desire Disorder - Therapeutics Development
  3. Pipeline Overview
  4. Pipeline by Companies
  5. Products under Development by Companies
  6. Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
  7. Assessment by Target
  8. Assessment by Mechanism of Action
  9. Assessment by Route of Administration
  10. Assessment by Molecule Type
  11. Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
  • Emotional Brain BV
  • GlaxoSmithKline Plc
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • Strategic Science & Technologies LLC

For more information about this report visit https://www.researchandmarkets.com/research/p434gr/female_hypoactive?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20171219006045/en/

Business Wire
www.businesswire.com

Last updated on: 19/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.